{"id":"NCT04615273","sponsor":"Ascendis Pharma Endocrinology Division A/S","briefTitle":"A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency","officialTitle":"foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-03","primaryCompletion":"2023-11-02","completion":"2023-12-01","firstPosted":"2020-11-04","resultsPosted":"2025-01-15","lastUpdate":"2025-01-15"},"enrollment":264,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Growth Hormone Deficiency","Endocrine System Diseases","Hormone Deficiency"],"interventions":[{"type":"DRUG","name":"Lonapegsomatropin","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Somatropin","otherNames":[]}],"arms":[{"label":"Lonapegsomatropin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Somatropin","type":"ACTIVE_COMPARATOR"}],"summary":"A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily somatropin product). This is a global trial conducted in, but not limited to, the United States, Europe, and Asia.","primaryOutcome":{"measure":"Change From Baseline in Trunk Percent Fat at Week 38","timeFrame":"Baseline, Week 38","effectByArm":[{"arm":"Lonapegsomatropin","deltaMin":-1.68,"sd":null},{"arm":"Placebo","deltaMin":0.37,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"23 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":113,"countries":["United States","Armenia","Australia","Canada","Denmark","France","Georgia","Germany","Greece","Israel","Italy","Japan","Malaysia","Netherlands","New Zealand","Poland","Romania","Serbia","Slovakia","South Korea","Spain","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":89},"commonTop":["COVID-19","Arthralgia","Nasopharyngitis","Headache","Upper respiratory tract infection"]}}